Scarica l'app Stockscreener
15.18
4.65%
-0.74
Pre-mercato:
15.69
0.51
+3.36%
Precedente Chiudi:
$15.92
Aprire:
$15.97
Volume 24 ore:
1.77M
Relative Volume:
0.54
Capitalizzazione di mercato:
$949.20M
Reddito:
$16.10M
Utile/perdita netta:
$-198.97M
Rapporto P/E:
-4.3609
EPS:
-3.4809
Flusso di cassa netto:
$-183.99M
1 W Prestazione:
-2.82%
1M Prestazione:
-36.83%
6M Prestazione:
-68.04%
1 anno Prestazione:
+2.78%
Intervallo 1D:
$15.00
$16.14
Intervallo di 1 settimana:
$14.17
$17.72
Portata 52W:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
15.18 | 949.20M | 16.10M | -198.97M | -183.99M | -3.4809 |
VRTX
Vertex Pharmaceuticals Inc
|
448.62 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
741.69 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
677.50 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.05 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
275.69 | 30.60B | 5.36B | 287.73M | 924.18M | 2.5229 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2026-03-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
uniQure Faces Securities Fraud Lawsuit After FDA Approval Delay - National Today
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - GlobeNewswire Inc.
Gartner, Inc. Securities Fraud Class Action Result of Reduced Guidance Disclosure and 48% Stock Decline - GlobeNewswire Inc.
Driven Brands Holdings Inc. Securities Fraud Class Action Result of Erroneous Financial Statements and 39% Stock Decline - GlobeNewswire Inc.
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - GlobeNewswire Inc.
Liquidity Mapping Around (QURE) Price Events - Stock Traders Daily
uniQure Investors Sue Company Over Huntington’s Disease Drug Study Claims - TipRanks
QURE Shareholder Alert: uniQure N.V. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - PR Newswire
UNIQURE N.V. (QURE) Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action - marketscreener.com
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Holzer & Holzer, LLC Reminds Investors of April 13, 2026 - GlobeNewswire
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit - PR Newswire
Barclays Maintains uniQure (QURE) Rating, Lowers Price Target | QURE Stock News - GuruFocus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure Lawsuit – QURE - GlobeNewswire
uniQure (NASDAQ:QURE) Shares Down 4.9% After Analyst Downgrade - MarketBeat
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
Barclays Maintains uniQure (QURE) Rating, Lowers Price Target | - GuruFocus
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors - GlobeNewswire
QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - Sahm
ROSEN, SKILLED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before ... - Bluefield Daily Telegraph
ROSEN, SKILLED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
uniQure N.V. (QURE) Class Action Lawsuit: Investors Face April 13, 2026, Deadline - The Globe and Mail
UniQure surges following departure of key FDA official - MSN
Market Review: What are the analyst revisions for JPMPRPCIs uniQure NV stock a good investment in YEARDividend Hike & Growth Focused Entry Point Reports - baoquankhu1.vn
Investment Recap: Can uniQure NV continue delivering strong returnsMarket Activity Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
NASDAQ: QURE: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE) - The Globe and Mail
QURE stock crashes 32% in a week: Here's what you should know - MSN
QURE DEADLINE NOTICE: uniQure N.V. Investors Encouraged to Contact Kirby McInerney LLP By April 13, 2026 - ACCESS Newswire
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V.QURE - Morningstar
uniQure Faces Investor Lawsuit Reminder - Intellectia AI
uniQure N.V. stock surges on positive Phase 1/ 2 data for AMT-130 in Huntington's disease - AD HOC NEWS
QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data - PR Newswire
Energy Moves: Does uniQure NV have strong fundamentals2026 Volume Leaders & Reliable Price Breakout Signals - baoquankhu1.vn
uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit - GlobeNewswire
QURE INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - TMX Newsfile
uniQure N.V. $QURE Shares Sold by JPMorgan Chase & Co. - MarketBeat
uniQure N.V. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights - Benzinga
QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data - GlobeNewswire Inc.
Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline – Company AnnouncementFT.com - Financial Times
uniQure N.V. Stockholders Should Contact Robbins LLP for Information About Leading the QURE Class Action - PharmiWeb.com
UNIQURE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. ... - Bluefield Daily Telegraph
UNIQURE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
uniQure (NASDAQ:QURE) Shares Up 5%Still a Buy? - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming DeadlinesQURE - PR Newswire
QURE DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - ChartMill
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds uniQure N.V. Investors of ... - Bluefield Daily Telegraph
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard - GlobeNewswire
uniQure Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure LawsuitQURE - PR Newswire
Uniqure NV (QURE) - MSN
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.80%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):